{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:26:55Z","timestamp":1792045615900,"version":"4.4.0"},"reference-count":93,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"unspecified","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,2,9]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>T cell engagers (TCEs) recruit T cells to the tumor microenvironment (TME) to induce antitumor immune responses. TCEs have demonstrated promising clinical responses in patients with metastatic castration-resistant prostate cancer and have advanced into phase 3 clinical trials. Here we provide an overview of the mechanisms of action of TCEs, including both CD3-targeted and CD28-targeted agents, and review the clinical development of these agents for prostate cancer. We propose a path forward for TCEs in prostate cancer, in which innovative clinical trials will facilitate a biological understanding of mechanisms of efficacy and toxicity to inform: (1) development of predictive biomarkers for patient selection; (2) rational combination strategies; and (3) targeted treatments for toxicity management, ultimately delivering broad clinical benefit for patients with lethal prostate cancer.<\/jats:p>","DOI":"10.1136\/jitc-2025-013905","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:10:19Z","timestamp":1771949419000},"page":"e013905","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["The path forward for T cell engagers in patients with prostate cancer"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct05125016","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05519449","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05997615","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06691984","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06613100","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06555796","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04898634","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct07164443","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct07225946","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04702737","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03972657","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06085664","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06826768","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06095089","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05585034","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05369000","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06691984","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06693687","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04571398","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05812274","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06826768","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05125016","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06095089","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Sumit K","family":"Subudhi","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6806-1294","authenticated-orcid":false,"given":"Bilal A","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin K","family":"Zarrabi","sequence":"additional","affiliation":[{"name":"Thomas Jefferson University, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William K","family":"Kelly","sequence":"additional","affiliation":[{"name":"Thomas Jefferson University, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles G","family":"Drake","sequence":"additional","affiliation":[{"name":"Johnson & Johnson Innovative Medicine, Raritan, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"2026062607452197000_14.2.e013905.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.12.011"},{"key":"2026062607452197000_14.2.e013905.2","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1158\/1078-0432.CCR-23-3403","article-title":"Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer","volume":"30","author":"Lenis","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026062607452197000_14.2.e013905.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.10.029"},{"key":"2026062607452197000_14.2.e013905.4","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/s41586-024-08290-3","article-title":"Evolution of myeloid-mediated immunotherapy resistance in prostate cancer","volume":"637","author":"Lyu","year":"2025","journal-title":"Nature New Biol"},{"key":"2026062607452197000_14.2.e013905.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01638"},{"key":"2026062607452197000_14.2.e013905.6","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002919","article-title":"Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment","volume":"9","author":"Subudhi","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026062607452197000_14.2.e013905.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.08.007"},{"key":"2026062607452197000_14.2.e013905.8","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.annonc.2024.09.004","article-title":"Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial","volume":"35","author":"van Wilpe","year":"2024","journal-title":"Ann Oncol"},{"key":"2026062607452197000_14.2.e013905.9","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/314628a0","article-title":"Hybrid antibodies can target sites for attack by T cells","volume":"314","author":"Staerz","year":"1985","journal-title":"Nature New Biol"},{"key":"2026062607452197000_14.2.e013905.10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.15.7021"},{"key":"2026062607452197000_14.2.e013905.11","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-0547"},{"key":"2026062607452197000_14.2.e013905.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103485"},{"key":"2026062607452197000_14.2.e013905.13","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2307980"},{"key":"2026062607452197000_14.2.e013905.14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1247"},{"key":"2026062607452197000_14.2.e013905.15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00281-024-01013-w","article-title":"Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy","volume":"46","author":"Hughes","year":"2024","journal-title":"Semin Immunopathol"},{"key":"2026062607452197000_14.2.e013905.16","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1182\/blood-2024-193916","article-title":"Cytokine Release Syndrome: Trends with T Cell Engaging Bispecifics from a Systematic Review of Licensing Applications","volume":"144","author":"Radtke","year":"2024","journal-title":"Blood"},{"key":"2026062607452197000_14.2.e013905.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4"},{"key":"2026062607452197000_14.2.e013905.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"2026062607452197000_14.2.e013905.19","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.16176"},{"key":"2026062607452197000_14.2.e013905.20","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698"},{"key":"2026062607452197000_14.2.e013905.21","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1200\/JCO.2025.43.5_suppl.128","article-title":"Prevalence of adverse events following T-cell engaging bispecific antibodies (bsAbs) and chimeric antigen receptor (CAR) T-cell therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC): A meta-analysis","volume":"43","author":"Saxena","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026062607452197000_14.2.e013905.22","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"2026062607452197000_14.2.e013905.23","doi-asserted-by":"crossref","DOI":"10.1177\/17562872231182219","article-title":"Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer","volume":"15","author":"Zarrabi","year":"2023","journal-title":"Ther Adv Urol"},{"key":"2026062607452197000_14.2.e013905.24","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.eururo.2025.02.001","article-title":"T-cell Engagers in Prostate Cancer","volume":"87","author":"Hage Chehade","year":"2025","journal-title":"Eur Urol"},{"key":"2026062607452197000_14.2.e013905.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026062607452197000_14.2.e013905.26","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"2026062607452197000_14.2.e013905.27","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2217\/imt-2020-0256","article-title":"Pasotuxizumab, a Bite \u00ae Immune Therapy for Castration-Resistant Prostate Cancer: Phase I, Dose-Escalation Study Findings","volume":"13","author":"Hummel","year":"2021","journal-title":"Immunotherapy"},{"key":"2026062607452197000_14.2.e013905.28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1261070","article-title":"Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy","volume":"14","author":"Penny","year":"2023","journal-title":"Front Immunol"},{"key":"2026062607452197000_14.2.e013905.29","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1158\/1078-0432.CCR-23-2978","article-title":"A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer","volume":"30","author":"Dorff","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026062607452197000_14.2.e013905.30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3725"},{"key":"2026062607452197000_14.2.e013905.31","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1200\/JCO.2021.39.15_suppl.5013","article-title":"Results of an ongoing phase 1\/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"39","author":"De Bono","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026062607452197000_14.2.e013905.32","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0061"},{"key":"2026062607452197000_14.2.e013905.33","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1200\/JCO.2024.42.16_suppl.2536","article-title":"Updated results on the bispecific PSMAxCD3 antibody CC-1 for treatment of prostate cancer","volume":"42","author":"Heitmann","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026062607452197000_14.2.e013905.34","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.clgc.2023.02.010","article-title":"Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer","volume":"21","author":"Lim","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"2026062607452197000_14.2.e013905.35","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS295","article-title":"Phase 1\/2 study of REGN4336 alone or in combination with cemiplimab or nezastomig in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"43","author":"Kelly","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026062607452197000_14.2.e013905.36","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2006.00391.x"},{"key":"2026062607452197000_14.2.e013905.37","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015956"},{"key":"2026062607452197000_14.2.e013905.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.008"},{"key":"2026062607452197000_14.2.e013905.39","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002488","article-title":"Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release","volume":"9","author":"Dang","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026062607452197000_14.2.e013905.40","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e14587","article-title":"Phase 1 clinical trial of AMG 340, a prostate-specific membrane antigen (PSMA)-targeted T-cell engager with a novel low-affinity CD3 binding domain designed to mitigate toxicity for the treatment of metastatic castration-resistant prostate cancer (mCRPC)","volume":"42","author":"Falchook","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026062607452197000_14.2.e013905.41","doi-asserted-by":"crossref","unstructured":"DiRaimondo T , Budimir N , Shenhav S , et al . 1325\u2005Preclinical activity and safety profile of janx007, a novel psma-targeting tumor-activated t cell engager for treatment of metastatic castration-resistant prostate cancer. SITC 37th Annual Meeting (SITC 2022) Abstracts; 2022 doi:10.1136\/jitc-2022-SITC2022.1325","DOI":"10.1136\/jitc-2022-SITC2022.1325"},{"key":"2026062607452197000_14.2.e013905.42","unstructured":"Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC. BusinessWire; 2024. Available: https:\/\/www.businesswire.com\/news\/home\/20241202674893\/en\/Janux-Announces-Doses-Selected-for-Phase-1b-Expansion-Trials-Supported-by-Encouraging-Efficacy-and-Safety-Profile-Observed-in-Phase-1a-Dose-Escalation-for-JANX007-in-mCRPC"},{"key":"2026062607452197000_14.2.e013905.43","unstructured":"Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates. 2025. Available: https:\/\/investors.januxrx.com\/investor-media\/news\/news-details\/2025\/Janux-Therapeutics-Initiates-Phase-1b-Expansion-Studies-with-JANX007-in-Patients-with-Prostate-Cancer-and-Provides-Program-Updates\/default.aspx"},{"key":"2026062607452197000_14.2.e013905.44","unstructured":"Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC. 2025. Available: https:\/\/investors.januxrx.com\/investor-media\/news\/news-details\/2025\/Janux-Announces-Encouraging-Efficacy-and-Safety-Profile-from-Ongoing-Phase-1-Clinical-Trial-for-JANX007-in-mCRPC\/default.aspx"},{"key":"2026062607452197000_14.2.e013905.45","unstructured":"Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC. Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC.. Vir Biotechnology, Inc; 2025. Available: https:\/\/investors.vir.bio\/news\/news-details\/2025\/Vir-Biotechnology-Announces-Encouraging-Safety-and-Efficacy-Data-in-Ongoing-Dose-Escalation-Trials-for-Dual-Masked-T-Cell-Engagers-VIR-5818-in-Solid-Tumors-and-VIR-5500-in-mCRPC\/default.aspx"},{"key":"2026062607452197000_14.2.e013905.46","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1158\/0008-5472.CAN-22-1433","article-title":"Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer","volume":"83","author":"Chou","year":"2023","journal-title":"Cancer Res"},{"key":"2026062607452197000_14.2.e013905.47","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41408-017-0023-x","article-title":"CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment","volume":"7","author":"Mejstr\u00edkov\u00e1","year":"2017","journal-title":"Blood Cancer J"},{"key":"2026062607452197000_14.2.e013905.48","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0984"},{"key":"2026062607452197000_14.2.e013905.49","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1158\/2159-8290.CD-23-0964","article-title":"Xaluritamig, a STEAP1 \u00d7 CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study","volume":"14","author":"Kelly","year":"2024","journal-title":"Cancer Discov"},{"key":"2026062607452197000_14.2.e013905.50","doi-asserted-by":"crossref","first-page":"S963","DOI":"10.1016\/j.annonc.2024.08.1679","article-title":"1598P Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study","volume":"35","author":"Kelly","year":"2024","journal-title":"Ann Oncol"},{"key":"2026062607452197000_14.2.e013905.51","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1158\/1078-0432.CCR-25-0950","article-title":"Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer","volume":"31","author":"Shen","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026062607452197000_14.2.e013905.52","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1200\/JCO-25-00678","article-title":"Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study","volume":"43","author":"Stein","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026062607452197000_14.2.e013905.53","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.1450"},{"key":"2026062607452197000_14.2.e013905.54","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205142"},{"key":"2026062607452197000_14.2.e013905.55","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae313","article-title":"A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancer","volume":"30","author":"Calvo","year":"2025","journal-title":"Oncologist"},{"key":"2026062607452197000_14.2.e013905.56","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav0891","article-title":"Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer","volume":"11","author":"Puca","year":"2019","journal-title":"Sci Transl Med"},{"key":"2026062607452197000_14.2.e013905.57","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1158\/1078-0432.CCR-25-1211","article-title":"Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study","volume":"31","author":"Aggarwal","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026062607452197000_14.2.e013905.58","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3389\/fonc.2018.00069","article-title":"Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers","volume":"8","author":"Soundararajan","year":"2018","journal-title":"Front Oncol"},{"key":"2026062607452197000_14.2.e013905.59","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1259"},{"key":"2026062607452197000_14.2.e013905.60","doi-asserted-by":"publisher","DOI":"10.1084\/jem.182.2.459"},{"key":"2026062607452197000_14.2.e013905.61","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/356607a0","article-title":"CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones","volume":"356","author":"Harding","year":"1992","journal-title":"Nature New Biol"},{"key":"2026062607452197000_14.2.e013905.62","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2009.00771.x"},{"key":"2026062607452197000_14.2.e013905.63","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba2325","article-title":"Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy","volume":"12","author":"Waite","year":"2020","journal-title":"Sci Transl Med"},{"key":"2026062607452197000_14.2.e013905.64","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw7888","article-title":"A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies","volume":"12","author":"Skokos","year":"2020","journal-title":"Sci Transl Med"},{"key":"2026062607452197000_14.2.e013905.65","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1292"},{"key":"2026062607452197000_14.2.e013905.66","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.154"},{"key":"2026062607452197000_14.2.e013905.67","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS293","article-title":"A phase 1\/2 study of nezastomig (anti-PSMA\u00d7CD28) with or without cemiplimab (anti\u2013PD-1) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and clear cell renal cell carcinoma (ccRCC)","volume":"43","author":"Siddiqui","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026062607452197000_14.2.e013905.68","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-CT064","article-title":"Abstract CT064: Updated safety and efficacy results from a phase 1\/2 study of nezastomig, a first-in-class co-stimulatory PSMA\u00d7CD28 bispecific antibody (bsAb), plus cemiplimab (anti-PD-1) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"85","author":"Siddiqui","year":"2025","journal-title":"Cancer Res"},{"key":"2026062607452197000_14.2.e013905.69","article-title":"646 A pilot presurgical trial of REGN5678 (Anti-PSMAxCD28) in patients with high-risk, localized prostate cancer followed by radical prostatectomy","volume":"12","author":"Siddiqui","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026062607452197000_14.2.e013905.70","doi-asserted-by":"crossref","first-page":"S1000","DOI":"10.1016\/j.annonc.2024.08.1740","article-title":"1659TiP A phase I, first-in-human, open-label, multicenter, trial-in-progress of the safety, tolerability, and preliminary efficacy of JNJ-87189401 (PSMA-CD28 bispecific antibody) combined with JNJ-78278343 (KLK2-CD3 bispecific antibody) for advanced prostate cancer","volume":"35","author":"Stein","year":"2024","journal-title":"Ann Oncol"},{"key":"2026062607452197000_14.2.e013905.71","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1158\/1535-7163.MCT-24-0327","article-title":"A B7-H3-Targeted CD28 Bispecific Antibody Enhances the Activity of Anti-PD-1 and CD3 T-cell Engager Immunotherapies","volume":"24","author":"Moore","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"2026062607452197000_14.2.e013905.72","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-SITC2023.0764"},{"key":"2026062607452197000_14.2.e013905.73","unstructured":"Xencor reports third quarter 2024 financial results. BusinessWire; 2024. Available: https:\/\/www.businesswire.com\/news\/home\/20241106077662\/en\/Xencor-Reports-Third-Quarter-2024-Financial-Results?feedref=JjAwJuNHiystnCoBq_hl-bQQCakZDujohEJegUyaJwquReQ0P23MrIoWkrUSV24ZevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxbNWfZlBntHS6jpH5ROLXsTFMkl05DM8ABqeyBleEmzJA%3D%3D"},{"key":"2026062607452197000_14.2.e013905.74","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/JLB.2MR1219-233R","article-title":"\u03b1\u03b2 and \u03b3\u03b4 T cell receptors: Similar but different","volume":"107","author":"Morath","year":"2020","journal-title":"J Leukoc Biol"},{"key":"2026062607452197000_14.2.e013905.75","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1200\/JCO.2023.41.6_suppl.153","article-title":"Early dose escalation of LAVA-1207, a novel bispecific gamma-delta T-cell engager (Gammabody), in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Mehra","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026062607452197000_14.2.e013905.76","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2672","article-title":"Phase I\/II trial of LAVA-1207, a novel bispecific gamma-delta T-cell engager alone, or with low dose IL-2 or pembrolizumab, in metastatic castration resistant prostate cancer (mCRPC)","volume":"42","author":"Mehra","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026062607452197000_14.2.e013905.77","article-title":"A pilot study of the ApricityCare program for early detection and management of treatment-related adverse events in patients with metastatic cancer","volume":"43","author":"Chen","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026062607452197000_14.2.e013905.78","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.ccell.2021.07.019","article-title":"High-frequency temperature monitoring for early detection of febrile adverse events in patients with cancer","volume":"39","author":"Flora","year":"2021","journal-title":"Cancer Cell"},{"key":"2026062607452197000_14.2.e013905.79","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-025-01222-y","article-title":"Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed\/refractory multiple myeloma","volume":"15","author":"Davis","year":"2025","journal-title":"Blood Cancer J"},{"key":"2026062607452197000_14.2.e013905.80","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc4220","article-title":"ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC","volume":"12","author":"Goswami","year":"2020","journal-title":"Sci Transl Med"},{"key":"2026062607452197000_14.2.e013905.81","doi-asserted-by":"publisher","DOI":"10.1016\/J.CCELL.2021.04.014"},{"key":"2026062607452197000_14.2.e013905.82","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1158\/1538-7445.AM2025-727","article-title":"Abstract 727: Association of baseline tumor and peripheral biomarker features with efficacy in metastatic castration-resistant prostate cancer patients treated with xaluritamig","volume":"85","author":"Decato","year":"2025","journal-title":"Cancer Res"},{"key":"2026062607452197000_14.2.e013905.83","doi-asserted-by":"crossref","unstructured":"Siddiqui I . T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy. 2019;50:195\u2013211. doi:10.1016\/j.immuni.2018.12.021","DOI":"10.1016\/j.immuni.2018.12.021"},{"key":"2026062607452197000_14.2.e013905.84","doi-asserted-by":"crossref","first-page":"S1212","DOI":"10.1016\/j.annonc.2025.08.3001","article-title":"2385MO Translational analyses of T cell phenotypes and their association with clinical efficacy in the first-in-human (FIH) trial of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer (mCRPC)","volume":"36","author":"Autio","year":"2025","journal-title":"Ann Oncol"},{"key":"2026062607452197000_14.2.e013905.85","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1200\/JCO.2023.41.16_suppl.2521","article-title":"Safety and early biologic effects of phase 1 PERIO-01 trial of pressure-enabled drug delivery (PEDD) of TLR9 agonist SD-101 and immune checkpoint inhibition (ICI) in uveal melanoma metastatic to the liver (MUM)","volume":"41","author":"Montazeri","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026062607452197000_14.2.e013905.86","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1158\/1078-0432.CCR-23-2585","article-title":"Backfilling Patients in Phase I Dose-Escalation Trials Using Bayesian Optimal Interval Design (BOIN)","volume":"30","author":"Zhao","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026062607452197000_14.2.e013905.87","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/s41467-023-37874-2","article-title":"Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy","volume":"14","author":"Bhatia","year":"2023","journal-title":"Nat Commun"},{"key":"2026062607452197000_14.2.e013905.88","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1200\/JCO.2025.43.16_suppl.5016","article-title":"177 Lu-PSMA-617 with ipilimumab (ipi) and nivolumab (nivo) in metastatic castration-resistant prostate cancer (mCRPC): An investigator-initiated phase 2 trial (EVOLUTION; ANZUP2001)","volume":"43","author":"Sandhu","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026062607452197000_14.2.e013905.89","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/JCO.2025.43.5_suppl.140","article-title":"Metastasis-directed therapy (MDT) plus androgen deprivation therapy (ADT) for oligometastatic prostate cancer (omPC): Primary results of the EXTEND continuous ADT (cADT) basket plus combined analysis with the updated intermittent ADT (iADT) basket and immune correlatives","volume":"43","author":"Sherry","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026062607452197000_14.2.e013905.90","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","article-title":"Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial","volume":"9","author":"Tang","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026062607452197000_14.2.e013905.91","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006624corr1"},{"key":"2026062607452197000_14.2.e013905.92","first-page":"125","article-title":"Pasotuxizumab, a BiTE\u00ae immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings","volume":"13","author":"Hummel","year":"2021","journal-title":"Immunotherapy (Los Angel)"},{"key":"2026062607452197000_14.2.e013905.93","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1200\/JCO.2024.42.16_suppl.5012","article-title":"Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC)","volume":"42","author":"Aggarwal","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-013905","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:45:57Z","timestamp":1782485157000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-013905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":93,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,24]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/jitc-2025-013905"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-013905","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}